Navigation Links
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
Date:5/1/2013

, NS5a inhibitors, and nucleotide polymerase inhibitors for interferon-free treatment of HCV and Hepatitis B Virus (HBV).

At the same time, wider access to personalised medical treatment is encouraging the uptake of novel, improved therapeutics. The availability of drugs that target viral hepatitis infections according to distinct genetic strains is promoting market development.

HBV and HCV are prevalent among illegal drug users and migrant populations across Europe. However, low awareness means that many affected patients remain untreated.

"Wider access to national counselling programmes and enhancing awareness among high-risk populations such as drug users, infected mothers, and migrants is critical," concludes Chopda. "Such initiatives, together with free screening and reduced treatment costs, will help limit the incidence and impact of Hepatitis B and C."

If you are interested in more information on this research, please send an email to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com

Analysis of the European Hepatitis B and C Therapeutics Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan's related research services include: European HIV Drugs Market, European Hepatitis B and C Diagnostics Market, U.S. Hepatitis C Market, and U.S HIV/AIDS Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressi
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
4. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
5. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
6. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
9. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
10. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
11. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
Breaking Medicine Technology:Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
... YORK, Dec. 23, 2010 Dr. David Samadi, robotic ... of Urology, and Chief of Robotics and Minimally Invasive Surgery ... continues to break barriers by sharing his robotic surgery ... worldwide. Today, Samadi, a pioneer surgeon in the field of ...
... 23, 2010 Generex Biotechnology Corporation ( www.generex.com ) (OTC ... to extend the closing date of its previously announced acquisition ... www.globalmeddirect.com ) to June 1, 2011. The Company ... decision of the Nasdaq Listing and Hearing Review Council affirming ...
Cached Medicine Technology:Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 2Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 3Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3
(Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
(Date:9/2/2014)... Obesity is associated with many health risks, including heart ... found a possible way to mitigate one often-overlooked risk: ... study led by Sheldon H. Jacobson, a professor of ... obesity rates are associated with a decrease in seatbelt ... laws are in effect. , "Primary seatbelt laws lead ...
(Date:9/2/2014)... Betmiga) has been approved since December 2012 for the ... benefit assessment pursuant to the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ... over the appropriate comparator therapy specified by the Federal ... regard to side effects: Dry mouth was less common ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Welcome to ... the over 4.6 million Canadians living with the disease, ... “Voices of Arthritis” video series featuring well-known Canadians from ... ,      Lloyd Robertson , veteran news ... silver medal skier ,      Amy Cotton ...
(Date:9/2/2014)... has become an increasing concern to health officials both ... City Department of Health and Mental Hygiene, the number ... triple the number of such deaths in 2000. Much ... rise in nonmedical prescription opioid (PO) use among teens ... among youth who transitioned from POs to heroin. ...
Breaking Medicine News(10 mins):Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: